Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anaesthetics are commonly categorized in two classes as per their functions like local anaesthetic and general anaesthetic. General anaesthetic are chemical agents which produces drug induced absence of sensitivities. Depth of anaesthesia for maintenance of surgical anaesthesia is achieved by combination of drugs or alone drugs. The general anaesthetic action is produced by various chemical agents, inhalation agents like xenon and nitrous oxide or halogenated compounds. Intravenous anaesthetics are classified by categories like barbiturates, benzodiazepines, opioids, ketamine and alpha-2 adrenoreceptor agonists. The general anaesthetic agents are designed to attain the loss of consciousness and pain insensitivity at the time of operative procedures.
The Asia Pacific general anaesthetic drug market is witnessing tremendous growth during forecast period 2021-2027. The anaesthetic drugs are used in management of pain during the operative procedures and used for reduce patient consciousness. The dynamic factors like increasing number of surgeries is propelling the market growth of Asia Pacific general anaesthetic drug market. Surgical complexities and patient safety expectation is also refuelling the market growth of Asia Pacific general anaesthetic drug market. However, lack of healthcare facilities in underdeveloped countries and remote areas is restraining the market growth of Asia Pacific general anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the general anaesthetic drug market. In addition, complete analysis of changes on general anaesthetic drug expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The Asia Pacific general anaesthetic drug market is bifurcated by drug molecules, route of administrations, end user and country.
The Asia Pacific general anaesthetic drug market is comprised of drug molecules like isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol and other. In which thiopental is also contributing in the market growth. Thiopental sodium is also called as sodium pentothal, which is a short acting barbiturate used as general anaesthetic. It is the thiobarbiturate analogue of pentobarbital and analogue of thiobarbital. It shows onset of action in 30-40 seconds and action lasts up to the 5-10 minutes. The thiopental is metabolised by liver and have half life of 5.5 to 26 hours.
The route of administration like intravenous and inhalational are comprised in the Asia Pacific general anaesthetic drug market. In which inhalational route is also contributing in the market growth. The rising rate of surgical procedures is propelling growth of segment. The adoption of advanced equipment like anaesthetic vaporizer is also refuelling the market growth of the Asia Pacific general anaesthetic drug market. Inhalation agents like nitrous oxide, halothane and other agents are used in the daily practise. They have risk of side effects like nausea, vomiting, cardiac arrhythmias, neurotoxicity hepatotoxicity and other.
The Asia Pacific general anaesthetic drug market is comprised of end users like hospitals, speciality clinics and ambulatory surgical centres. In which hospitals is likely to dominate the market in 2020. The growing population increases the burden of healthcare facilities which leads to increase in number of hospitals is propelling the growth of market. The adoption of advance technologies of surgeries is also refuelling the market growth of Asia Pacific general anaesthetic drug market.
The Asia Pacific general anaesthetic drug market is studied for countries like India, Japan, China, Australia and South Korea. In which Japan is anticipated to witness rapid growth during the forecast period 2021-2027. The rising technological advancement in healthcare industries is propelling the growth of Asia Pacific general anaesthetic drug market. The growing rate of surgical procedures is also refuelling the market growth of Asia Pacific general anaesthetic drug market. The new product launchings is also elevating the market growth of Asia Pacific general anaesthetic drug market.
The major key players in general anaesthetic drug market are Baxter International Inc. (Us), Hikma Pharmaceuticals Plc (Uk), Pfizer Inc. (Us), Piramal Enterprises Limited (India), Abbvie (Us), Fresenius Se & Co. Kgaa (Germany), Par Pharmaceutical (Us), Teva Pharmaceuticals (Israel), Viatris/Mylan (Us), Novartis Ag (Us), Abbott Laboratories (Us), Astrazeneca Plc (Us), F. Hoffmann-La Roche (Switzerland), Glaxosmithkline Plc (Uk), Gilead Sciences Inc. (Us), Bayer Ag (Germany), Merck & Co. Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (Us), Akorn (Us) and Apotex (Canada) among other are analysed.
August 2020: The Fresenius Kabi launched its first medication with smart label comprised with radio-frequency identification technology. The first RFID smart labelled product, Diprivan (propofol) 200mg per 20mL (10mg per mL) injectables Emulsion, USP.
July 2020: Acacia Pharma a group of PLC received U.S. FDA permission for BYFAVO (remimazolam) for injection for induction and maintenance of operational sedation in adults undergoing procedures which lasts up to 30 minutes or less.
May 2020: Hikma Pharmaceutical PLC, which is a multinational pharmaceutical company, launched their propofol injectable emulsion, USP. In 20ml, 50ml, 100ml vials.
January 2020: Novartis AG acquired Aspen’s Japanese operations focused on generics and off-patent medicines.
The study comprised of general anaesthetic drug market. In which study analysed the various segments of the market. The general anaesthetic drug market is bifurcated by drug molecule, route of administration and end users. The study also comprised of dominating segment of the market. In the study it is profound that the drug molecule segment is dominated by propofol. Likewise, route of administration is dominated by intravenous route and end user segment is dominated by hospitals. The study also imparts the geographical section of the market and it concludes that Japan is dominating the market in 2020. The study also comprised of impact on COVID-19 on the general anaesthetic drug market and it conclude that there is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also imparts the major key players operating in the regions.
Why to buy this report
